Kristin Higgins, MD

home / authors / kristin-higgins-md

Articles

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, MedStar Georgetown University Hospital;Kristin Higgins, MD
July 6th 2020

Read More

Second- and Third-Line Treatment for ES-SCLC

Second- and Third-Line Treatment for ES-SCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, MedStar Georgetown University Hospital;Kristin Higgins, MD
July 6th 2020

Read More

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, MedStar Georgetown University Hospital;Kristin Higgins, MD
July 6th 2020

Read More

Expert Approaches to Treating Extensive Stage SCLC

Expert Approaches to Treating Extensive Stage SCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, MedStar Georgetown University Hospital;Kristin Higgins, MD
July 6th 2020

Read More

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, MedStar Georgetown University Hospital;Kristin Higgins, MD
July 6th 2020

Read More

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, MedStar Georgetown University Hospital;Kristin Higgins, MD
July 6th 2020

Read More

Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC

Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC

Kristin Higgins, MD
April 24th 2014

Locally advanced non-small cell lung cancer (NSCLC) remains a challenging disease to treat, with a 5-year survival rate for patients with unresectable stage III disease of approximately 20%, even after definitive radiation therapy and concurrent chemotherapy.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data